Soluble Fms-like Tyrosine Kinase-1 (sFlt-1)
Soluble forms like tyrosine kinase-1 are tyrosine kinase proteins with antiangiogenic properties. A non-membrane-associated splice variant of VEGF receptor 1, sFlt-1 binds the angiogenic factors VEGF and PlGF, reducing blood vessel growth by reducing free VEGF and PlGF concentrations.
sFlt-1/PLGF ratio is valuable for assessing the severity of preeclampsia and diagnosing early-onset preeclampsia.
Eclampsia is one of five hypertensive conditions in pregnancy and is a common life-threatening condition for pregnant women worldwide.
During the development of preeclampsia, sFlt-1 levels are generally elevating in maternal circulating serum, placental growth factor (PlGF) levels are decreasing, and concentrations of cardiac markers are also detected to be advancing.
Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) Products
|Mouse Anti-human Human Sflt-1 mAb|
For immunodiagnostic: ELISA, LFA, CLIA
|Recombinant Soluble Fms salt-1 (Eukaryotic Expression)||For immunodiagnostic: ELISA, LFA, CLIA|
Soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), also known as soluble fms-like tyrosine kinase-1 (sFlt-1), was initially discovered in human umbilical vein endothelial cells and is a tyrosine kinase Active glycoprotein formed by different splicing methods from VEGFR-1 mRNA. sFlt-1 is a factor found in recent years that is believed to play an important role in anti-angiogenesis, mainly produced by the placenta. It plays a role in blood circulation by antagonizing the biological function of VEGF.
Preeclampsia (PE) is an idiopathic disease during pregnancy, with an incidence of 2% to 8%, and is one of the leading causes of adverse pregnancy outcomes and death in mothers and children.
The anti-angiogenic factor, soluble Fms-like tyrosine kinase-1 (sFlt-1), is significantly increased in the blood circulation of pregnant women with PE, which can antagonize vascular endothelial growth factor (vascular endothelial growth factor, VEGF), causing extensive vascular endothelial damage, leading to clinical manifestations such as hypertension and proteinuria. In recent years, sFlt-1 has become one of the predictors of PE, and scholars have begun to pay attention to the application value of sFlt-1 as a therapeutic target in preventing and treating PE.
- Cardiac Troponin I (cTnI)
- Myoglobin (Myo)
- Creatine Kinase-MB (CKMB)
Heart-type Fatty Acid Binding Protein (H-FABP)
- N-terminal Pro B Type Natriuretic Peptide (NT-proBNP)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Cardiac Troponin T (cTnT)
Pepsinogens I (PGI)
Human Epididymis 4 (HE4)
- Prostate-Specific Antigen (PSA)
- Squamous Cell Carcinoma (SCC)
- Neuron-Specific Enolase (NSE)
- Cytokeratin 19 Fragment (CYFRA21-1)
- Human Progastrin-releasing Peptide (ProGRP Tumor Marker)
- Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA II Tumor Marker)
- Inflammatory Marker
- Influenza (Flu)
- Estradiol (E2)
Anti-human Mullerian Hormone (AMH)
Placental Growth Factor (PLGF)
- Soluble Fms-like Tyrosine Kinase-1 (sFlt-1)
Follicle Stimulating Hormone(FSH)
Human Chorionic Gonadotropin (Total HCG β)
- Progesterone (Prog)
- Thyroid Function
- Glucose Metabolism
- Bone Marker
Heterophilic Blocking Reagent
- Animal Diagnostics